Pre-existing endothelial cell activation predicts vasoplegia after mitral valve surgery

Interactive Cardiovascular and Thoracic Surgery

Volumn 17, Issue 3, 2013, Pages 523-530

  Kortekaas, Kirsten A ^a   Lindeman, Jan H N ^a   Reinders, Marlies E J ^a   Palmen, Meindert ^a   Klautz, Robert J M ^a   De Groot, Philip G ^b   Roest, Mark ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Endothelial cell activation; Surgery; Vasoplegia

Indexed keywords

ANGIOPOIETIN 2; CELL MARKER; INTERLEUKIN 8; OSTEOPROTEGERIN; PADGEM PROTEIN; VON WILLEBRAND FACTOR;

AGED; ARTICLE; BLOOD SAMPLING; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FEMALE; HEART INDEX; HEART MUSCLE REPERFUSION; HUMAN; MALE; MEAN ARTERIAL PRESSURE; MITRAL ANNULOPLASTY; MOLECULAR PATHOLOGY; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; VASOPLEGIA;

ENDOTHELIAL CELL ACTIVATION; SURGERY; VASOPLEGIA;

AGED; AREA UNDER CURVE; ARTERIAL PRESSURE; BIOLOGICAL MARKERS; CARDIAC SURGICAL PROCEDURES; CARDIOTONIC AGENTS; CHI-SQUARE DISTRIBUTION; ENDOTHELIAL CELLS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MITRAL VALVE; P-SELECTIN; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; RISK FACTORS; ROC CURVE; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION; VASOCONSTRICTOR AGENTS; VASOPLEGIA; VON WILLEBRAND FACTOR;

EID: 84882805394     PISSN: 15699293     EISSN: 15699285     Source Type: Journal    
DOI: 10.1093/icvts/ivt243     Document Type: Article

References (25)

1. Byrne JG, Leacche M, Paul S, Mihaljevic T, Rawn JD, Shernan SK et al. Risk factors and outcomes for 'vasoplegia syndrome' following cardiac transplantation. Eur J Cardiothorac Surg 2004;25:327-32
2. Levin MA, Lin HM, Castillo JG, Adams DH, Reich DL, Fischer GW. Early on-cardiopulmonary bypass hypotension and other factors associated with vasoplegic syndrome. Circulation 2009;120:1664-71
3. Leyh RG, Kofidis T, Struber M, Fischer S, Knobloch K, Wachsmann B et al. Methylene blue: The drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass? J Thorac Cardiovasc Surg 2003;125:1426-31
4. Gomes WJ, Carvalho AC, Palma JH, Teles CA, Branco JN, Silas MG et al. Vasoplegic syndrome after open heart surgery. J Cardiovasc Surg (Torino) 1998;39:619-23
5. Lowenstein CJ, Morrell CN, Yamakuchi M. Regulation of Weibel-Palade body exocytosis. Trends Cardiovasc Med 2005;15:302-8
6. van Mourik JA, Romani de Wit T, Voorberg J. Biogenesis and exocytosis of Weibel-Palade bodies. Histochem Cell Biol 2002;117:113-22
7. Bertuglia S, Ichimura H, Fossati G, Parthasarathi K, Leoni F, Modena D et al. ITF1697, a stable Lys-Pro-containing peptide, inhibits Weibel-Palade body exocytosis induced by ischemia/reperfusion and pressure elevation. Mol Med 2007;13:615-24
8. Boyle EM Jr, Pohlman TH, Johnson MC, Verrier ED. Endothelial cell injury in cardiovascular surgery: The systemic inflammatory response. Ann Thorac Surg 1997;63:277-84
9. Zannettino AC, Holding CA, Diamond P, Atkins GJ, Kostakis P, Farrugia A et al. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol 2005;204:714-23
10. Lip GY, Blann A. von Willebrand factor: A marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997;34:255-65
11. Bonow RO. Chronic mitral regurgitation and aortic regurgitation: Have indications for surgery changed? J Am Coll Cardiol 2013;61:693-701
12. Colson PH, Bernard C, Struck J, Morgenthaler NG, Albat B, Guillon G. Post cardiac surgery vasoplegia is associated with high preoperative copeptin plasma concentration. Crit Care 2011;15:R225-62
13. Mekontso-Dessap A, Houel R, Soustelle C, Kirsch M, Thebert D, Loisance DY. Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. Ann Thorac Surg 2001;71: 1428-32
14. Kortekaas KA, van der Pol P, Lindeman JH, Baan CC, van Kooten C, Klautz RJ. No prominent role for terminal complement activation in the early myocardial reperfusion phase following cardiac surgery. Eur J Cardiothorac Surg 2012;41:117-25 .
15. Kortekaas KA, Lindeman JH, Versteegh MI, van Beelen E, Kleemann R, Klautz RJ. Heart failure determines the myocardial inflammatory response to injury. Eur J Heart Fail 2013;15:400-7
16. Borchiellini A, Fijnvandraat K, ten Cate JW, Pajkrt D, van Deventer SJ, Pasterkamp G et al. Quantitative analysis of von Willebrand factor propeptide release in vivo: Effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood 1996;88: 2951-8
17. Argenziano M, Chen JM, Choudhri AF, Cullinane S, Garfein E, Weinberg AD et al. Management of vasodilatory shock after cardiac surgery: Identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 1998;116:973-80
18. Sugawara J, Komine H, Hayashi K, Yoshizawa M, Otsuki T, Shimojo N et al. Reduction in alpha-adrenergic receptor-mediated vascular tone contributes to improved arterial compliance with endurance training. Int J Cardiol 2009;135:346-52
19. Sun X, Zhang L, Hill PC, Lowery R, Lee AT, Molyneaux RE et al. Is incidence of postoperative vasoplegic syndrome different between off-pump and on-pump coronary artery bypass grafting surgery? Eur J Cardiothorac Surg 2008;34:820-5
20. Sun X, Boyce SW, Herr DL, Hill PC, Zhang L, Corso PJ et al. Is vasoplegic syndrome more prevalent with open-heart procedures compared with isolated on-pump CABG surgery? Cardiovasc Revasc Med 2011;12: 203-9
21. Wagner DD, Fay PJ, Sporn LA, Sinha S, Lawrence SO, Marder VJ. Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells. Proc Natl Acad Sci USA 1987;84:1955-9
22. Habe K, Wada H, Ito-Habe N, Hatada T, Matsumoto T, Ohishi K et al. Plasma ADAMTS13, von Willebrand factor (VWF) and VWF propeptide profiles in patients with DIC and related diseases. Thromb Res 2012;129: 598-602
23. Claus RA, Bockmeyer CL, Sossdorf M, Losche W. The balance between von-Willebrand factor and its cleaving protease ADAMTS13: Biomarker in systemic inflammation and development of organ failure? Curr Mol Med 2010;10:236-48
24. Holdright DR, Hunt BJ, Parratt R, Segal H, Clarke D, Taggart D et al. The effects of cardiopulmonary bypass on systemic and coronary levels of von Willebrand factor. Eur J Cardiothorac Surg 1995;9:18-21
25. Valen G, Blomback M, Sellei P, Lindblom D, Vaage J. Release of von Willebrand factor by cardiopulmonary bypass, but not by cardioplegia in open heart surgery. Thromb Res 1994;73:21-9